Mangiferin Encapsulation Matrix for Acid-Stable Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Mangiferin's low solubility in acidic gastric fluids and rapid clearance from the gastrointestinal tract limit its bioavailability and clinical efficacy, hindering its potential to improve cognitive functions such as working memory, selective attention, and executive function.
Innovation Solution
A composition comprising mango extract rich in mangiferin is encapsulated within a hydrophilic carrier matrix with an embedded alkalizer, enhancing solubility and clinical efficacy by maintaining an alkaline environment, using a proprietary encapsulation technology.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mangiferin is administered orally, then it can reach the target site in the brain, but its low solubility in acidic gastric fluids and rapid clearance from the gastrointestinal tract limit its bioavailability and clinical efficacy
Solution Approach 1:
The patent changes the pH parameter of the gastric environment by incorporating an alkalizer into the composition. This alkalizer neutralizes the acidic gastric fluids, creating a more favorable pH environment for mangiferin dissolution and absorption, thereby improving its solubility and bioavailability without requiring complex delivery systems
Solution Approach 2:
The patent creates a composite composition by combining mangiferin with an alkalizer in a specific formulation. This composite approach allows the alkalizer to modify the gastric environment while mangiferin maintains its neuroprotective and cognitive-enhancing properties, achieving improved bioavailability through material composition rather than complex delivery mechanisms
2Reliability
If mangiferin is used to inhibit COMT and improve cognitive functions, then working memory, selective attention and executive function can be enhanced, but its rapid clearance from the gastrointestinal tract limits its clinical efficacy
Solution Approach 1:
The patent applies preliminary action by having the alkalizer ready in the composition to neutralize gastric acids before mangiferin encounters them. This pre-prepared chemical environment ensures optimal solubility conditions are immediately available upon ingestion, preventing rapid clearance and enhancing the duration of action in the bloodstream and brain
Solution Approach 2:
By changing the pH parameter through the alkalizer, the patent extends the time window for mangiferin absorption and circulation. The modified gastric environment slows down clearance rates, allowing mangiferin to maintain therapeutic levels longer in the system, thereby improving clinical efficacy for cognitive enhancement
Data Source
AI summary
The present invention relates to a proprietary encapsulation technology where in a composition comprising mangiferin will maintain in-situ alkaline environment and minimizes the precipitation issues of mangiferin in the acidic environment. A composition of mangiferin has been disclosed. A natural hydrophilic plant-based carrier along with a selected alkalizer is being embedded in the encapsulation matrix which subsequently acts as a platform to ensure the alkaline environment with better solubility of bioactive across the physiological pH range.